BIOSPECIFICS TECHNOLOGIES CORP Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2011-12-09: Form 8-K; Period of report 2011-12-09; Description 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; Details 5.02.
- 2011-11-16: Form 8-K; Period of report 2011-11-16; Description 7.01 Regulation FD Disclosure; Details 7.01.
- 2011-11-08: Form 8-K; Period of report 2011-11-08; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2011-09-16: Form 8-K; Period of report 2011-09-16; Description 7.01 Regulation FD Disclosure; Details 7.01.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2011-12-09 | 8-K | 2011-12-09 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 Effective December 6, 2011, the Company’s Board of Directors (the “Board”), at the recommendation of the Nominating and Corporate Governance Committee, authorized an increase in the size of the Board from seven to eight directors and appointed Mr. George Gould to serve as a director in the second class of directors, with a term expiring at the Company’s annual meeting of stockholders in 2013. | form8k.htm |
| 2011-11-16 | 8-K | 2011-11-16 | 7.01 Regulation FD Disclosure | 7.01 Our President, Thomas L. Wegman, will present to various investors beginning on November 16, 2011 using the presentation materials furnished as Exhibit 99.1 hereto and which are incorporated herein by reference. | form8k.htm |
| 2011-11-08 | 8-K | 2011-11-08 | 2.02 Results of Operations and Financial Condition | 2.02 On November 8, 2011, the Company announced its financial and operating results for the fiscal quarter ended September 30, 2011. | form8k.htm |
| 2011-09-16 | 8-K | 2011-09-16 | 7.01 Regulation FD Disclosure | 7.01 Our President, Thomas L. Wegman, will present to various investors beginning on September 16, 2011 using the presentation materials furnished as Exhibit 99.1 hereto and which are incorporated herein by reference. | form8k.htm |
| 2011-09-07 | 8-K | 2011-09-07 | 7.01 Regulation FD Disclosure | 7.01 Our President, Thomas L. Wegman, will present to various investors beginning on September 6, 2011 using the presentation materials furnished as Exhibit 99.1 hereto and which are incorporated herein by reference. | form8k.htm |
| 2011-09-01 | 8-K | 2011-09-01 | 1.01 Entry into a Material Definitive Agreement; 7.01 Regulation FD Disclosure | 1.01 As previously reported, on June 3, 2004 the Company and Auxilium Pharmaceuticals, Inc. (“Auxilium”) entered into a development and license agreement (the “Original Agreement”). | form8k.htm |
| 2011-08-09 | 8-K | 2011-08-08 | 2.02 Results of Operations and Financial Condition | 2.02 On August 9, 2011, the Company announced its financial and operating results for the fiscal quarter ended June 30, 2011. | form8k.htm |
| 2011-06-20 | 8-K | 2011-06-20 | 8.01 Other Events | 8.01 On June 20, 2011, the Company issued a press release announcing that its Board of Directors has authorized the repurchase of up to $2 million of its outstanding common stock. | form8k.htm |
| 2011-06-16 | 8-K | 2011-06-16 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 The 2011 annual meeting of stockholders of the Company (the “2011 Annual Meeting”) was held on June 13, 2011. | form8k.htm |
| 2011-06-09 | 8-K | 2011-06-09 | 7.01 Regulation FD Disclosure | 7.01 Our President, Thomas L. Wegman, will present to various investors beginning on June 9, 2011 using the presentation materials furnished as Exhibit 99.1 hereto and which are incorporated herein by reference. | form8k.htm |
| 2011-06-03 | 8-K | 2011-06-02 | 8.01 Other Events | 8.01 On June 1, 2011, the Company issued a press release announcing that positive data for XIAPEX® were presented at the XVIth Annual Federation of European Societies for Surgery of the Hand Congress which took place in Oslo, Norway on May 26-28, 2011. | form8k.htm |
| 2011-05-20 | 8-K | 2011-05-20 | 8.01 Other Events | 8.01 On May 20, 2011, the Company issued a press release announcing that Auxilium Pharmaceuticals, Inc. has received a $7.5 million regulatory milestone from Pfizer, Inc. following the sale of XIAPEX® in Germany, a major EU market. | form8k.htm |
| 2011-05-11 | 8-K | 2011-05-11 | 7.01 Regulation FD Disclosure | 7.01 Our President, Thomas L. Wegman, will present to various investors beginning on May 11, 2011 using the presentation materials furnished as Exhibit 99.1 hereto and which are incorporated herein by reference. | form8k.htm |
| 2011-05-10 | 8-K | 2011-05-10 | 2.02 Results of Operations and Financial Condition | 2.02 On May 10, 2011, the Company announced its financial and operating results for the fiscal quarter ended March 31, 2011. | form8k.htm |
| 2011-05-02 | 8-K | 2011-05-02 | 7.01 Regulation FD Disclosure | 7.01 Our President, Thomas L. Wegman, will present to various investors in May 2011 using the presentation materials furnished as Exhibit 99.1 hereto and which are incorporated herein by reference. | form8k.htm |
| 2011-04-26 | 8-K/A | 2011-04-26 | 2.02 Results of Operations and Financial Condition | 2.02 On March 11, 2011, the Company announced its financial and operating results for the fiscal quarter and full year ended December 31, 2010. | form8ka.htm |
| 2011-04-15 | 8-K | 2011-04-15 | 7.01 Regulation FD Disclosure | 7.01 Our President, Thomas L. Wegman, will present to various investors beginning on April 15, 2011 using the presentation materials furnished as Exhibit 99.1 hereto and which are incorporated herein by reference. | d8k.htm |
| 2011-04-11 | 8-K | 2011-04-11 | 8.01 Other Events | 8.01 On April 11, 2011, the Company announced the launch of XIAPEX® by Pfizer Inc. for treatment of Dupuytren’s Contracture in Europe. | d8k.htm |
| 2011-03-14 | 8-K | 2011-03-14 | 7.01 Regulation FD Disclosure | 7.01 Our President, Thomas L. Wegman, will present to various investors beginning on March 14, 2011 using the presentation materials furnished as Exhibit 99.1 hereto and which are incorporated herein by reference. | form8k.htm |
| 2011-03-11 | 8-K | 2011-03-11 | 2.02 Results of Operations and Financial Condition | 2.02 On March 11, 2011, the Company announced its financial and operating results for the fiscal quarter and full year ended December 31, 2010. | form8k.htm |
| 2011-03-07 | 8-K | 2011-03-07 | 8.01 Other Events | 8.01 Our President, Thomas L. Wegman, will present to various investors in March 2011 using the presentation materials furnished as Exhibit 99.1 hereto and which are incorporated herein by reference. | form8k.htm |
| 2011-03-01 | 8-K | 2011-03-01 | 8.01 Other Events | 8.01 On March 1, 2011, the Company announced that Pfizer Inc. received approval from the European Medicines Agency to market XIAPEX® (collagenase clostridium histolyticum) in Europe for the treatment of Dupuytren’s contracture. | form8k.htm |
| 2011-02-11 | 8-K | 2011-02-11 | 7.01 Regulation FD Disclosure | 7.01 Our President, Thomas L. Wegman, will present to various investors in February 2011 using the presentation materials furnished as Exhibit 99.1 hereto and which are incorporated herein by reference. | form8k.htm |
| 2011-02-04 | 8-K | 2011-02-04 | 1.01 Entry into a Material Definitive Agreement; 3.03 Material Modification to Rights of Security Holders | 1.01 On February 3, 2011, the Company entered into an amendment (the “Amendment”) to the Rights Agreement, dated as of May 14, 2002 and previously amended June 19, 2003, between the Company and OTC Corporate Transfer Service Company, as rights agent (the “Rights Agreement”). 3.03 The information set forth under “Item 1.01 Entry into a Material Definitive Agreement” of this Current Report on Form 8-K is incorporated into this Item 3.03 by reference. | d8k.htm |
| 2011-01-10 | 8-K | 2011-01-10 | 7.01 Regulation FD Disclosure | 7.01 Our President, Thomas L. Wegman, will present to various investors in January 2011 using the presentation materials furnished as Exhibit 99.1 hereto and which are incorporated herein by reference. | form8k.htm |
| 2011-01-07 | 8-K | 2011-01-07 | 8.01 Other Events | 8.01 On January 6, 2011, the Company announced promising results from its study Chien-802 showing dramatic reductions in canine lipoma following injections with purified injectable collagenase. | form8k.htm |